The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Wall Street analysts forecast that Amicus Therapeutics (FOLD) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year increase of 190.9%. It is ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Amicus (FOLD – Research Report), with a price target ...

Amicus Therapeutics, Inc. PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...